Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

79.96 -1.56 (-1.91%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
Via The Motley Fool
Topics Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Dow Jones Stock to Target This Week and 2 to Avoid
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors. 
Via StockStory
Topics Stocks
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
Merck & Co Unusual Options Activity For July 15
Via Benzinga
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
Via Stocktwits
P/E Ratio Insights for Merck & Co
Via Benzinga
This House of Representative Just Bought Up To $30K In 3M Stock
Via Benzinga
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile. 
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued. 
Via Chartmill
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Kazia's early trial data show significant CTC and cluster reduction in a breast cancer patient treated with Paxalisib, Keytruda, and chemotherapy. 
Via Benzinga
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations. 
Via Benzinga
Topics World Trade
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
The takeover target just launched its first drug last summer. Shares have mostly trended higher since. 
Via Investor's Business Daily
Topics Government
Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. 
Via Stocktwits
Topics Government
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
2 S&P 500 Stocks with Promising Prospects and 1 to Question
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
What's going on in today's session: S&P500 gap up and gap down stocks
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Merck's Hypertension Drug On FDA Fast Track For Label Expansion
Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact. 
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare
MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors. 
Via Chartmill
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.